Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.60 |
| ▸ | PPARA | Q07869 | 8/20 | 0.60 |
| ▸ | PPARG | P37231 | 5/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499481 | 0.92 | PPARD (0.60) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6222387 | 0.89 | PPARD (0.48) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6223036 | 0.87 | PPARD (0.47) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6221860 | 0.85 | PPARD (0.47) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6264863 | 0.84 | PPARD (0.47) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6220211 | 0.83 | PPARD (0.47) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL5017180 | 0.82 | PPARD (0.60) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL5016708 | 0.79 | PPARD (0.52) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL3539359 | 0.79 | PPARD (0.65) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL30375840 | 0.79 | MAOB (0.52) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1816550-B | Indolyl derivatives substituted with a thiazole ring and their use as PPAR modulators | HOFFMANN LA ROCHE | 2010-04-28 | — | — | CN | disclosed |
| EP-1644368-B1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7235572-B2 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7109222-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2006-09-19 | — | — | US | disclosed |
| CN-1816550-A | Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | CN | disclosed |
| EP-1644368-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | KALYPSYS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2005-05-19 | — | — | US | disclosed |
| US-6867224-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER-LAMBERT COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| WO-2005005423-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-01-06 | — | — | US | disclosed |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
| US-20050113422-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | PPARD 2/4885PPARA 1/4885PPARG 3/4885 |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885PPARG 3/4885 |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | PPARD 2/4885PPARA 1/4885PPARG 3/4885 |
| US-20050107442-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | PPARD 2/4885PPARA 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.